Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis-Reference-Cited by-同舟云学术

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis

Published:2015-08 Issue:2 Volume:149 Page:350-355.e2
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Brandse Johannan F.,van den Brink Gijs R.,Wildenberg Manon E.,van der Kleij Desiree,Rispens Theo,Jansen Jeroen M.,Mathôt Ron A.,Ponsioen Cyriel Y.,Löwenberg Mark,D’Haens Geert R.A.M.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference32 articles.

1. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

2. Infliximab for induction and maintenance therapy for ulcerative colitis;Rutgeerts;N Engl J Med,2005

3. Assessing response and loss of response to biological therapies in IBD;Yanai;Am J Gastroenterol,2011

4. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease;Baert;N Engl J Med,2003

5. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease;Maser;Clin Gastroenterol Hepatol,2006

Cited by 346 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letter to the editor: Real-world evidence of combined treatment of biologics and exclusive enteral nutrition in patients with ileum-dominant Crohn's disease: A multicenter study;Clinical Nutrition ESPEN;2024-10

2. Predicting Outcome after Acute Severe Ulcerative Colitis: A Contemporary Review and Areas for Future Research;Journal of Clinical Medicine;2024-08-01

3. What are the benefits of therapeutic drug monitoring in the optimization of adalimumab therapy? a systematic review and meta-analysis up to 2022;Frontiers in Pharmacology;2024-07-08

4. Infliximab Tissue Concentrations in Patients With Stable Ulcerative Colitis Are Correlated With More Durable Infliximab-associated Disease Remission;Inflammatory Bowel Diseases;2024-05-08

5. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05